Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade

Jan 15 (Reuters) - Boston Scientific is buying medical equipment maker Penumbra in a deal valued at ​about $14.5 billion, to expand its vascular pipeline.

The move ‌adds to a growing list of high-profile transactions over the ‌past decade by U.S. pharmaceutical companies to acquire promising therapies in fields ranging from oncology, neurology to rare diseases and obesity.

Below are some of the major deals ⁠involving U.S.-based pharma ‌and biotech firms from the past decade

Year Acquirer Target Deal Description

Value

2026 Boston

Scientific $14.5 To expand

Penumbra billion vascular

pipeline

2025 Abbott < Exact up to To gain

Sciences $23 access to

ABT.N> billion Exact

Sciences'

cancer tests,

including

flagship

colorectal

cancer test

Cologuard

2025 Merck Cidara $9.2 To ‍gain

Therapeut billion access to

ics Cidara's

experimental

drug for flu

prevention

2025 Pfizer Metsera $10 To gain a

billion foothold in

the

fast-growing

obesity

treatment

market

2025 Merck & Verona About $10 Strengthens

Co Pharma billion Merck's

respiratory

portfolio

amid looming

Keytruda

patent cliff

2025 Johnson & Intra-Cel $14.6 Expands J&J's

Johnson lular billion footprint in

Therapies brain disease

treatments

2024 Novo Catalent $16.5 Boosts

Holdings billion manufacturing

(includin capacity for

g debt), Novo

$11.5 Nordisk's

billion popular

(excludin obesity drug

g debt) Wegovy

2023 Merck & Prometheu $10.8 Adds

Co s billion experimental

Bioscienc treatment for

es ulcerative

colitis and

Crohn's

disease and

builds up

presence ​in

immunology

2023 Bristol Karuna BMY gains a

Myers Therapeut $14 promising

Squibb ics billion antipsychotic

medicine as

patents on

its older

therapies

near their

expiry

2023 Pfizer Seagen $43 Builds

billion Pfizer's

cancer

portfolio

amid decline

in ‌sales for

COVID-related

products and

generic

competition

2022 Amgen Horizon $27.8 Buyout,

Therapeut billion biggest in

ics the sector in

2022,

fortifies

rare diseases

portfolio

2022 Pfizer Biohaven $11.6 Pfizer bets

Pharmaceu billion big on a new

tical class of

Holding migraine

drugs

2021 Merck & Co Acceleron About Diversifies

Pharma $11.5 Merck's

billion portfolio

beyond

cancer

2021 Ginkgo Soaring $17.5 Ginkgo goes

Bioworks Eagle million public

Acquisiti through a

on merger with a

blank-check

vehicle

backed by

former

Hollywood

executives

Harry Sloan

and Jeff

Sagansky

2020 AstraZenec Alexion $39 AstraZeneca's

a Pharmaceu billion largest ever

ticals deal to

diversify

away from its

cancer

business,

betting on

rare-disease

and

immunology

drugs

2020 Bristol MyoKardia About $13 Bolster

Myers billion Bristol's

Squibb portfolio of

heart disease

treatments

2020 Gilead Immunomed $21 Strengthens